Kunihiko Umekita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kunihiko Umekita has a total of 211 co-authors. Here are the top co-authors by number of shared publications:
Akihiko Okayama
Department of Respirology, Rheumatology, Infectious Diseases and Neurology, Internal Medicine, University of Miyazaki , Miyazaki, Japan
11 shared publicationsIchiro Takajo
Division of Respirology, Rheumatology, Infectious Diseases, and Neurology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
11 shared publicationsShunichi Miyauchi
Division of Respirology, Rheumatology, Infectious Diseases and Neurology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki , Miyazaki
11 shared publications- Takeshi Kawaguchi
Division of Respirology, Rheumatology, Infectious Diseases, and Neurology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan
11 shared publications Yayoi Hashiba
Institute of Rheumatology, Miyazaki Zenjinkai Hospital, Miyazaki-shi , Miyazaki
11 shared publicationsChihiro Iwao
Division of Respirology, Rheumatology, Infectious Diseases and Neurology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki , Miyazaki
10 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Springer Nature in Scientific Reports
Targeting the gene encoding human T-cell leukemia virus type 1 basic zip factor via CRISPR/Cas9 potentially affects ATL cell survival
- 8 October 2026
- Published by Springer Nature in Scientific Reports
Open AccessTargeting the gene encoding human T-cell leukemia virus type 1 basic zip factor via CRISPR/Cas9 potentially affects ATL cell survival
- 5 October 2026
- Published by Oxford University Press (OUP) in Modern Rheumatology
Human T-cell leukaemia virus type 1-associated myelopathy in patients with rheumatoid arthritis: A case series highlighting functional disability and diagnostic challenges
Objectives: Although rheumatoid arthritis (RA) and human T-cell leukaemia virus type 1 (HTLV-1)–associated myelopathy/tropical spastic paraparesis (HAM/TSP) occasionally coexist, their clinical characteristics and patient outcomes remain poorly elucidated. Methods: We conducted a retrospective case series of five patients with RA complicated by HAM/TSP (HAM-RA) enrolled in the HTLV-1 Positive Rheumatoid Arthritis Miyazaki Registry. Clinical characteristics, functional status, quality of life, and HTLV-1–associated parameters were reviewed. Age- and sex-matched patients with HTLV-1–positive RA and HTLV-1–negative RA served as comparison groups. Results: All patients were women (median age, 67 years). HAM/TSP preceded RA onset in two patients, whereas RA developed first in three. Neurological disability substantially varies (Osame Motor Disability Scores of 2–11; three required wheelchair. Despite comparable RA disease activity, patients with HAM-RA demonstrated worse physical function and quality of life than controls. Patients with HAM-RA tended to have higher HTLV-1 proviral loads than HTLV-1–positive RA without HAM/TSP. Conclusions: HAM/TSP may develop before or after RA onset and cause substantial functional disability despite satisfactory control of arthritis. Screening for HTLV-1 may facilitate consideration of HAM/TSP and timely neurological evaluation. High proviral loads in patients with HAM-RA may warrant careful monitoring for the development of adult T-cell leukaemia/lymphoma.
- 5 October 2026
- Published by Oxford University Press (OUP) in Modern Rheumatology
Human T-cell leukaemia virus type 1-associated myelopathy in patients with rheumatoid arthritis: A case series highlighting functional disability and diagnostic challenges
Objectives: Although rheumatoid arthritis (RA) and human T-cell leukaemia virus type 1 (HTLV-1)–associated myelopathy/tropical spastic paraparesis (HAM/TSP) occasionally coexist, their clinical characteristics and patient outcomes remain poorly elucidated. Methods: We conducted a retrospective case series of five patients with RA complicated by HAM/TSP (HAM-RA) enrolled in the HTLV-1 Positive Rheumatoid Arthritis Miyazaki Registry. Clinical characteristics, functional status, quality of life, and HTLV-1–associated parameters were reviewed. Age- and sex-matched patients with HTLV-1–positive RA and HTLV-1–negative RA served as comparison groups. Results: All patients were women (median age, 67 years). HAM/TSP preceded RA onset in two patients, whereas RA developed first in three. Neurological disability substantially varies (Osame Motor Disability Scores of 2–11; three required wheelchair. Despite comparable RA disease activity, patients with HAM-RA demonstrated worse physical function and quality of life than controls. Patients with HAM-RA tended to have higher HTLV-1 proviral loads than HTLV-1–positive RA without HAM/TSP. Conclusions: HAM/TSP may develop before or after RA onset and cause substantial functional disability despite satisfactory control of arthritis. Screening for HTLV-1 may facilitate consideration of HAM/TSP and timely neurological evaluation. High proviral loads in patients with HAM-RA may warrant careful monitoring for the development of adult T-cell leukaemia/lymphoma.
- Open Access
- 21 September 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10  (4)
Quadruple-negative autoantibody status and interstitial lung disease progression in systemic sclerosis
Objectives: To evaluate the association between disease-specific autoantibody profiles and disease progression in systemic sclerosis-associated interstitial lung disease (SSc-ILD), with a focus on a quadruple-negative phenotype. Methods: This retrospective cohort study included 80 patients with SSc-ILD who were followed for at least 12 months at a single tertiary centre. ILD progression was defined according to the OMERACT criteria and/or worsening on high-resolution computed tomography. Autoantibody status was categorized based on four antibodies: anti-topoisomerase I, anti-centromere, anti-RNA polymerase III and anti-U1-RNP. Quadruple-negative (QN) was defined as negativity for all four antibodies. Factors associated with ILD progression were evaluated using multivariable logistic regression. Exploratory comprehensive autoantibody profiling was performed in patients with available stored serum samples. Results: During a median follow-up of 44.5 months, disease progression occurred in 32 of 80 patients with SSc-ILD. Anti-centromere antibody (ACA) positivity was associated with a lower risk of progression, whereas anti-topoisomerase I antibody positivity was not associated with disease progression (Model 2: OR 3.19, 95% CI 0.70–14.60). Compared with ACA positivity, QN status was associated with ILD progression (Model 2: OR 10.40, 95% confidence interval [CI] 1.77–60.70). However, CIs were wide. Exploratory analyses showed a high prevalence of anti-Ro-52 antibody positivity among patients with QN status. Conclusion: QN autoantibody status may be associated with an increased risk of ILD progression in SSc. The QN status may represent a heterogeneous serological category that could help identify patients who require closer clinical monitoring. However, these results are hypothesis-generating and require validation in larger, independent cohorts.
- 21 September 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10  (4)
Open AccessQuadruple-negative autoantibody status and interstitial lung disease progression in systemic sclerosis
Objectives: To evaluate the association between disease-specific autoantibody profiles and disease progression in systemic sclerosis-associated interstitial lung disease (SSc-ILD), with a focus on a quadruple-negative phenotype. Methods: This retrospective cohort study included 80 patients with SSc-ILD who were followed for at least 12 months at a single tertiary centre. ILD progression was defined according to the OMERACT criteria and/or worsening on high-resolution computed tomography. Autoantibody status was categorized based on four antibodies: anti-topoisomerase I, anti-centromere, anti-RNA polymerase III and anti-U1-RNP. Quadruple-negative (QN) was defined as negativity for all four antibodies. Factors associated with ILD progression were evaluated using multivariable logistic regression. Exploratory comprehensive autoantibody profiling was performed in patients with available stored serum samples. Results: During a median follow-up of 44.5 months, disease progression occurred in 32 of 80 patients with SSc-ILD. Anti-centromere antibody (ACA) positivity was associated with a lower risk of progression, whereas anti-topoisomerase I antibody positivity was not associated with disease progression (Model 2: OR 3.19, 95% CI 0.70–14.60). Compared with ACA positivity, QN status was associated with ILD progression (Model 2: OR 10.40, 95% confidence interval [CI] 1.77–60.70). However, CIs were wide. Exploratory analyses showed a high prevalence of anti-Ro-52 antibody positivity among patients with QN status. Conclusion: QN autoantibody status may be associated with an increased risk of ILD progression in SSc. The QN status may represent a heterogeneous serological category that could help identify patients who require closer clinical monitoring. However, these results are hypothesis-generating and require validation in larger, independent cohorts.
- Open Access
- 12 September 2026
- Published by Springer Nature in Retrovirology
Divergent proviral load trajectories and clonal dynamics of HTLV-1-infected cells during antirheumatic therapy in rheumatoid arthritis
- 12 September 2026
- Published by Springer Nature in Retrovirology
Open AccessDivergent proviral load trajectories and clonal dynamics of HTLV-1-infected cells during antirheumatic therapy in rheumatoid arthritis
- Open Access
- 25 August 2026
- Published by Springer Nature in Retrovirology
Clonal dynamics of HTLV-1–infected cells under immunosuppression stratify ATL risk and reveal restoration of Tax-specific immune surveillance
- 25 August 2026
- Published by Springer Nature in Retrovirology
Open AccessClonal dynamics of HTLV-1–infected cells under immunosuppression stratify ATL risk and reveal restoration of Tax-specific immune surveillance
- Open Access
- 30 April 2026
- Published by Springer Nature in Human Cell
- Vol. 39  (5) , 71
Heterogeneity of HTLV-1 proviral integration sites and internal structures in the ATL cell line MT-1
Human T-cell leukemia virus type 1 (HTLV-1) causes adult T-cell leukemia (ATL). The ATL-derived cell line MT-1 is used to study HTLV-1 biology and leukemogenesis. However, the proviral integration sites and internal structures of HTLV-1 are not comprehensively characterized in MT-1 cells. We analyzed two independently maintained MT-1 cell lines (MT-1 J and MT-1 M) using long PCR, quantitative PCR-based proviral load analysis, inverse long PCR, inverse PCR, integration site-specific PCR, direct sequencing, and Rapid Amplification of Integration Site without Interference by Genomic DNA contamination. Long PCR and proviral load analyses demonstrated that MT-1 cells harbor multiple full-length and defective HTLV-1 proviruses. MT-1 J cells exhibited reduced proviral load in the pX region, suggesting the presence of pX -lacking proviruses. Inverse long PCR and inverse PCR revealed at least five proviral integration sites in MT-1 J cells; MT-1 M cells contained three. Site-specific PCR confirmed the differential preservation of integration sites. Sequence analysis revealed two full-length proviruses and three type I defective proviruses with distinct internal deletions, including an unreported provirus with a large deletion encompassing pX . Rapid Amplification of Integration Site without Interference by Genomic DNA contamination identified major proviral clones shared between MT-1 J and MT-1 M cells, while revealing differences in clone frequencies and minor integration sites. The MT-1 cell line is a polyclonal population containing multiple full-length and defective HTLV-1 proviruses. Its proviral composition can change during long-term in vitro passaging. This heterogeneity should be considered when interpreting results obtained using MT-1 cells in HTLV-1 and ATL research.
- 30 April 2026
- Published by Springer Nature in Human Cell
- Vol. 39  (5) , 71
Open AccessHeterogeneity of HTLV-1 proviral integration sites and internal structures in the ATL cell line MT-1
Human T-cell leukemia virus type 1 (HTLV-1) causes adult T-cell leukemia (ATL). The ATL-derived cell line MT-1 is used to study HTLV-1 biology and leukemogenesis. However, the proviral integration sites and internal structures of HTLV-1 are not comprehensively characterized in MT-1 cells. We analyzed two independently maintained MT-1 cell lines (MT-1 J and MT-1 M) using long PCR, quantitative PCR-based proviral load analysis, inverse long PCR, inverse PCR, integration site-specific PCR, direct sequencing, and Rapid Amplification of Integration Site without Interference by Genomic DNA contamination. Long PCR and proviral load analyses demonstrated that MT-1 cells harbor multiple full-length and defective HTLV-1 proviruses. MT-1 J cells exhibited reduced proviral load in the pX region, suggesting the presence of pX -lacking proviruses. Inverse long PCR and inverse PCR revealed at least five proviral integration sites in MT-1 J cells; MT-1 M cells contained three. Site-specific PCR confirmed the differential preservation of integration sites. Sequence analysis revealed two full-length proviruses and three type I defective proviruses with distinct internal deletions, including an unreported provirus with a large deletion encompassing pX . Rapid Amplification of Integration Site without Interference by Genomic DNA contamination identified major proviral clones shared between MT-1 J and MT-1 M cells, while revealing differences in clone frequencies and minor integration sites. The MT-1 cell line is a polyclonal population containing multiple full-length and defective HTLV-1 proviruses. Its proviral composition can change during long-term in vitro passaging. This heterogeneity should be considered when interpreting results obtained using MT-1 cells in HTLV-1 and ATL research.
- Open Access
- 7 April 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10  (2)
The prevalence of pulmonary airway lesions is high in HTLV-1–positive rheumatoid arthritis: a cross-sectional observational study
Objective: To investigate whether human T cell leukaemia virus type 1 (HTLV-1) infection increases the risk of respiratory complications in patients with rheumatoid arthritis (RA), focusing on high-resolution computed tomography (HRCT) findings and clinical features. Methods: We retrospectively analyzed 30 HTLV-1-positive patients with RA enrolled in the HTLV-1 RA Miyazaki Registry who had undergone chest HRCT. For each patient, three age- and sex-matched HTLV-1-negative RA patients (n = 90) were recruited as controls. We compared pulmonary abnormalities on HRCT, RA disease activity, medication use, and systemic complications between the groups. In the HTLV-1-positive group, we also assessed the relationship between HTLV-1 proviral load (PVL) and pulmonary findings. Results: Although age and disease duration were similar between groups at the time of HRCT, HTLV-1-positive patients had significantly higher disease activity (CDAI: 6.4 vs.s 3.3, p = 0.01; SDAI: 7.28 vs.s 3.46, p = 0.01), greater glucocorticoid use (70% vs.s 36%), and lower biologic use (33% vs.s 61%). Abnormal pulmonary findings were observed in about 50% of both groups; however, bronchiolitis was more frequent in HTLV-1-positive patients, while interstitial lung disease patterns were comparable. HTLV-1 PVL did not differ significantly based on the presence or absence of pulmonary lesions. Conclusion: HTLV-1 infection may link to an increased prevalence of airway lesions, such as bronchiolitis and bronchiectasis, in RA patients. These findings suggest that screening for HTLV-1 should be considered in RA patients, especially those with respiratory symptoms or complications.
- 7 April 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10  (2)
Open AccessThe prevalence of pulmonary airway lesions is high in HTLV-1–positive rheumatoid arthritis: a cross-sectional observational study
Objective: To investigate whether human T cell leukaemia virus type 1 (HTLV-1) infection increases the risk of respiratory complications in patients with rheumatoid arthritis (RA), focusing on high-resolution computed tomography (HRCT) findings and clinical features. Methods: We retrospectively analyzed 30 HTLV-1-positive patients with RA enrolled in the HTLV-1 RA Miyazaki Registry who had undergone chest HRCT. For each patient, three age- and sex-matched HTLV-1-negative RA patients (n = 90) were recruited as controls. We compared pulmonary abnormalities on HRCT, RA disease activity, medication use, and systemic complications between the groups. In the HTLV-1-positive group, we also assessed the relationship between HTLV-1 proviral load (PVL) and pulmonary findings. Results: Although age and disease duration were similar between groups at the time of HRCT, HTLV-1-positive patients had significantly higher disease activity (CDAI: 6.4 vs.s 3.3, p = 0.01; SDAI: 7.28 vs.s 3.46, p = 0.01), greater glucocorticoid use (70% vs.s 36%), and lower biologic use (33% vs.s 61%). Abnormal pulmonary findings were observed in about 50% of both groups; however, bronchiolitis was more frequent in HTLV-1-positive patients, while interstitial lung disease patterns were comparable. HTLV-1 PVL did not differ significantly based on the presence or absence of pulmonary lesions. Conclusion: HTLV-1 infection may link to an increased prevalence of airway lesions, such as bronchiolitis and bronchiectasis, in RA patients. These findings suggest that screening for HTLV-1 should be considered in RA patients, especially those with respiratory symptoms or complications.
- Top Cited Papers
- 4 February 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65  (2)
Comparison of predictive validity of the Lupus Patient-Reported Outcome and Short-Form-12 for damage accrual in systemic lupus erythematosus
Objectives: A core set of patient-reported outcomes (PROs) for systemic lupus erythematosus (SLE) has not been established, and no studies have compared predictive validity of disease-specific and generic quality of life (QOL) instruments. We aimed to compare the predictive validity of the Lupus PRO and Medical Outcomes Study Short-Form-12 (SF-12) for damage accrual in patients with SLE. Methods: The Lupus PRO questionnaire contains both health-related (HR) and non-HR-QOL measures, whereas the SF-12 indices are the physical component summary (PCS), mental component summary (MCS), and role-social component summary (RCS). Damage accrual was evaluated using an increase of one unit in the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). We examined the association and predictive accuracy of the Lupus PRO and SF-12 scores at baseline for damage accrual using survival models for recurrent events. Results: Among 1326 patients, those with a higher HR-QOL on Lupus PRO at baseline showed significantly lower damage accrual (hazard ratio: 0.94, 95% confidence interval [CI]: 0.89–0.99), whereas higher PCS and RCS of SF-12 were associated with lower damage accrual (0.92, 95% CI: 0.86–0.98; 0.92, 95% CI: 0.86–0.99). The Akaike Information Criterion, Bayesian Information Criterion, C-index, and area under the curve were comparable between the Lupus PRO and SF-12. Only higher PCS of the SF-12 was associated with glucocorticoid-independent SDI. Conclusion: Predictive metrics and discriminatory performance were comparable between the Lupus PRO and SF-12. Our findings highlight both disease-specific and generic QOL measurements can be valuable options for core set outcomes.
- 4 February 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65  (2)
Top Cited PapersComparison of predictive validity of the Lupus Patient-Reported Outcome and Short-Form-12 for damage accrual in systemic lupus erythematosus
Objectives: A core set of patient-reported outcomes (PROs) for systemic lupus erythematosus (SLE) has not been established, and no studies have compared predictive validity of disease-specific and generic quality of life (QOL) instruments. We aimed to compare the predictive validity of the Lupus PRO and Medical Outcomes Study Short-Form-12 (SF-12) for damage accrual in patients with SLE. Methods: The Lupus PRO questionnaire contains both health-related (HR) and non-HR-QOL measures, whereas the SF-12 indices are the physical component summary (PCS), mental component summary (MCS), and role-social component summary (RCS). Damage accrual was evaluated using an increase of one unit in the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). We examined the association and predictive accuracy of the Lupus PRO and SF-12 scores at baseline for damage accrual using survival models for recurrent events. Results: Among 1326 patients, those with a higher HR-QOL on Lupus PRO at baseline showed significantly lower damage accrual (hazard ratio: 0.94, 95% confidence interval [CI]: 0.89–0.99), whereas higher PCS and RCS of SF-12 were associated with lower damage accrual (0.92, 95% CI: 0.86–0.98; 0.92, 95% CI: 0.86–0.99). The Akaike Information Criterion, Bayesian Information Criterion, C-index, and area under the curve were comparable between the Lupus PRO and SF-12. Only higher PCS of the SF-12 was associated with glucocorticoid-independent SDI. Conclusion: Predictive metrics and discriminatory performance were comparable between the Lupus PRO and SF-12. Our findings highlight both disease-specific and generic QOL measurements can be valuable options for core set outcomes.
- Open Access
- 10 December 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69  (12) , e0106225
Efficacy of favipiravir treatment for patients with severe fever with thrombocytopenia syndrome assessed with a historical control
Severe fever with thrombocytopenia syndrome (SFTS) is a disease caused by SFTS virus (SFTSV), an RNA virus, and endemic to Asia. The case fatality rate in Japan is estimated to be approximately 27%. Currently, no efficacious drugs are available. Favipiravir (FPV) has the potential to treat SFTS. However, no quantitative studies comparing FPV with conventional treatments have been conducted in the country. We conducted an open-label, interventional study in which patients with SFTS were administered FPV 1800 mg twice on the first day, followed by 800 mg twice daily for nine days. Additionally, we performed a retrospective observational study on patients with SFTS who received the best supportive care (BSC) without FPV treatment by collecting medical data from individuals at the same institutions. Patients aged 20–85 years were recruited, and blood samples were collected on Days 0 (pre-dose), 1, 3, 6, 9, 14, and 27 in the interventional study. Outcomes and laboratory parameters were compared by 1:1 matching using propensity score (PS). Thirty and 78 patients were enrolled in the FPV and the BSC groups, respectively. Twenty-three pairs were identified by PS matching. The risk ratio of fatality for the FPV group compared to the BSC group reduced to 0.500 after matching. Ferritin levels associated with hemophagocytosis severity were significantly different between the FPV and BSC groups on Days 3 to 9 after matching. No concerning serious adverse events were observed in the FPV group. This interventional study has been registered with the Japan Registry of Clinical Trials as jRCT2080223816 .
- 10 December 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69  (12) , e0106225
Open AccessEfficacy of favipiravir treatment for patients with severe fever with thrombocytopenia syndrome assessed with a historical control
Severe fever with thrombocytopenia syndrome (SFTS) is a disease caused by SFTS virus (SFTSV), an RNA virus, and endemic to Asia. The case fatality rate in Japan is estimated to be approximately 27%. Currently, no efficacious drugs are available. Favipiravir (FPV) has the potential to treat SFTS. However, no quantitative studies comparing FPV with conventional treatments have been conducted in the country. We conducted an open-label, interventional study in which patients with SFTS were administered FPV 1800 mg twice on the first day, followed by 800 mg twice daily for nine days. Additionally, we performed a retrospective observational study on patients with SFTS who received the best supportive care (BSC) without FPV treatment by collecting medical data from individuals at the same institutions. Patients aged 20–85 years were recruited, and blood samples were collected on Days 0 (pre-dose), 1, 3, 6, 9, 14, and 27 in the interventional study. Outcomes and laboratory parameters were compared by 1:1 matching using propensity score (PS). Thirty and 78 patients were enrolled in the FPV and the BSC groups, respectively. Twenty-three pairs were identified by PS matching. The risk ratio of fatality for the FPV group compared to the BSC group reduced to 0.500 after matching. Ferritin levels associated with hemophagocytosis severity were significantly different between the FPV and BSC groups on Days 3 to 9 after matching. No concerning serious adverse events were observed in the FPV group. This interventional study has been registered with the Japan Registry of Clinical Trials as jRCT2080223816 .
- 22 September 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65  (1)
Factors and outcomes related to clinical inertia in systemic lupus erythematosus: a multicentre LUNA cohort study
Objectives: This study aimed to identify predictors of clinical inertia in SLE management and to evaluate its impact on clinical outcomes. Methods: A historical cohort study was conducted using data from the multicentre LUNA cohort in Japan. The 365 patients with active disease 1 year before baseline (SLE Disease Activity Index score >4 or active gastrointestinal lesions or haemolytic anaemia) were classified by baseline disease activity and treatment intensification status over 1 year into non-intensification (n = 247) vs intensification (n = 118) groups. Furthermore, the clinical inertia group (n = 116), defined as sustained active disease without intensification, was compared with the non-clinical inertia group (n = 249), which comprised all other patients. Regression analyses assessed predictors and outcomes, including damage accrual, disease activity, quality of life (QoL) and patient satisfaction. Results: Non-intensification was associated with larger increases in glucocorticoid-related damage, while clinical inertia was linked to greater increases in overall and glucocorticoid-related damage. Non-intensification and clinical inertia correlated with a tendency towards reduced QoL across several domains. HCQ use and fewer concomitant immunosuppressants predicted non-intensification of treatment, whereas female sex and greater damage accrual predicted clinical inertia; older age showed similar but non-significant trends for both outcomes. Conclusion: Because clinical inertia can drive damage accrual and QoL deterioration, avoiding clinical inertia is a therapeutic priority. Regular reassessment of treatment strategy is essential for older patients, women and those with greater damage. Proactive tailoring of treatment to individual risk profiles can arrest clinical inertia and improve long-term outcomes.
- 22 September 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65  (1)
Factors and outcomes related to clinical inertia in systemic lupus erythematosus: a multicentre LUNA cohort study
Objectives: This study aimed to identify predictors of clinical inertia in SLE management and to evaluate its impact on clinical outcomes. Methods: A historical cohort study was conducted using data from the multicentre LUNA cohort in Japan. The 365 patients with active disease 1 year before baseline (SLE Disease Activity Index score >4 or active gastrointestinal lesions or haemolytic anaemia) were classified by baseline disease activity and treatment intensification status over 1 year into non-intensification (n = 247) vs intensification (n = 118) groups. Furthermore, the clinical inertia group (n = 116), defined as sustained active disease without intensification, was compared with the non-clinical inertia group (n = 249), which comprised all other patients. Regression analyses assessed predictors and outcomes, including damage accrual, disease activity, quality of life (QoL) and patient satisfaction. Results: Non-intensification was associated with larger increases in glucocorticoid-related damage, while clinical inertia was linked to greater increases in overall and glucocorticoid-related damage. Non-intensification and clinical inertia correlated with a tendency towards reduced QoL across several domains. HCQ use and fewer concomitant immunosuppressants predicted non-intensification of treatment, whereas female sex and greater damage accrual predicted clinical inertia; older age showed similar but non-significant trends for both outcomes. Conclusion: Because clinical inertia can drive damage accrual and QoL deterioration, avoiding clinical inertia is a therapeutic priority. Regular reassessment of treatment strategy is essential for older patients, women and those with greater damage. Proactive tailoring of treatment to individual risk profiles can arrest clinical inertia and improve long-term outcomes.